Carlos Requena
Carlos Requena has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Carlos Roca
A Centro de Investigaciones Biológicas (CIB-CSIC), C/Ramiro de Maeztu , Madrid , Spain
3 shared publications- Nuria Eugenia Campillo
Centro de Investigaciones Biológicas Margarita Salas (CIB Margarita Salas−CSIC)
3 shared publications - Víctor Sebastián-Pérez
Centro de Investigaciones Biológicas (CIB-CSIC), Madrid, Spain
3 shared publications - Ana Martinez
Centro de Investigaciones Biologicas, CSIC Madrid Spain
2 shared publications Concepción Pérez
D Instituto de Química Médica (IQM-CSIC) , C/Juan de la Cierva , Madrid , Spain
2 shared publicationsCatarina S. Takahashi
Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900, 14049-900, Ribeirão Preto, SP, Brazil; Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Avenida Bandeirantes, 3900, 14040-900, Ribeirão Preto, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 33 (1) , 1034-1047
Identification of new allosteric sites and modulators of AChE through computational and experimental tools
Allosteric sites on proteins are targeted for designing more selective inhibitors of enzyme activity and to discover new functions. Acetylcholinesterase (AChE), which is most widely known for the hydrolysis of the neurotransmitter acetylcholine, has a peripheral allosteric subsite responsible for amyloidosis in Alzheimer’s disease through interaction with amyloid β-peptide. However, AChE plays other non-hydrolytic functions. Here, we identify and characterise using computational tools two new allosteric sites in AChE, which have allowed us to identify allosteric inhibitors by virtual screening guided by structure-based and fragment hotspot strategies. The identified compounds were also screened for in vitro inhibition of AChE and three were observed to be active. Further experimental (kinetic) and computational (molecular dynamics) studies have been performed to verify the allosteric activity. These new compounds may be valuable pharmacological tools in the study of non-cholinergic functions of AChE.
- 1 January 2018
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 33 (1) , 1034-1047
Open AccessIdentification of new allosteric sites and modulators of AChE through computational and experimental tools
Allosteric sites on proteins are targeted for designing more selective inhibitors of enzyme activity and to discover new functions. Acetylcholinesterase (AChE), which is most widely known for the hydrolysis of the neurotransmitter acetylcholine, has a peripheral allosteric subsite responsible for amyloidosis in Alzheimer’s disease through interaction with amyloid β-peptide. However, AChE plays other non-hydrolytic functions. Here, we identify and characterise using computational tools two new allosteric sites in AChE, which have allowed us to identify allosteric inhibitors by virtual screening guided by structure-based and fragment hotspot strategies. The identified compounds were also screened for in vitro inhibition of AChE and three were observed to be active. Further experimental (kinetic) and computational (molecular dynamics) studies have been performed to verify the allosteric activity. These new compounds may be valuable pharmacological tools in the study of non-cholinergic functions of AChE.
- Open Access
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 773-791
From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 773-791
Open AccessFrom dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease
- Open Access
- 25 May 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 2403
Hybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery
Quantitative structure–activity relationship modeling using machine learning techniques constitutes a complex computational problem, where the identification of the most informative molecular descriptors for predicting a specific target property plays a critical role. Two main general approaches can be used for this modeling procedure: feature selection and feature learning. In this paper, a performance comparative study of two state-of-art methods related to these two approaches is carried out. In particular, regression and classification models for three different issues are inferred using both methods under different experimental scenarios: two drug-like properties, such as blood-brain-barrier and human intestinal absorption, and enantiomeric excess, as a measurement of purity used for chiral substances. Beyond the contrastive analysis of feature selection and feature learning methods as competitive approaches, the hybridization of these strategies is also evaluated based on previous results obtained in material sciences. From the experimental results, it can be concluded that there is not a clear winner between both approaches because the performance depends on the characteristics of the compound databases used for modeling. Nevertheless, in several cases, it was observed that the accuracy of the models can be improved by combining both approaches when the molecular descriptor sets provided by feature selection and feature learning contain complementary information.
- 25 May 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 2403
Open AccessHybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery
Quantitative structure–activity relationship modeling using machine learning techniques constitutes a complex computational problem, where the identification of the most informative molecular descriptors for predicting a specific target property plays a critical role. Two main general approaches can be used for this modeling procedure: feature selection and feature learning. In this paper, a performance comparative study of two state-of-art methods related to these two approaches is carried out. In particular, regression and classification models for three different issues are inferred using both methods under different experimental scenarios: two drug-like properties, such as blood-brain-barrier and human intestinal absorption, and enantiomeric excess, as a measurement of purity used for chiral substances. Beyond the contrastive analysis of feature selection and feature learning methods as competitive approaches, the hybridization of these strategies is also evaluated based on previous results obtained in material sciences. From the experimental results, it can be concluded that there is not a clear winner between both approaches because the performance depends on the characteristics of the compound databases used for modeling. Nevertheless, in several cases, it was observed that the accuracy of the models can be improved by combining both approaches when the molecular descriptor sets provided by feature selection and feature learning contain complementary information.